Want to see HK:1477 full AI Analyst Report?
Top Page
Ocumension Therapeutics
(1477)
Select Model
Select Model
Rating:51Neutral
Price Target:
HK$6.50
▼(-13.91% Downside)
Action:Reiterated
Date:07/17/26
The score is primarily driven by improving fundamentals and a strong, low-debt balance sheet, but is held back by persistent negative profitability and cash flow (continued reliance on external funding). Technically, the stock is recovering above short-term averages but remains below longer-term trends with a negative MACD, and valuation is constrained by negative earnings and no dividend information.
Positive Factors
Accelerating Revenue Growth
The sharp revenue increase indicates stronger commercial traction and product adoption. Sustained growth would improve operating leverage, expand the company’s presence in China’s ophthalmology market, and support future progress toward profitability.
Negative Factors
Persistent Unprofitability
Despite narrowing losses, the business has not yet demonstrated sustainable earnings. Continued negative EBIT and EBITDA limit internally funded expansion, weaken returns on equity, and leave profitability dependent on further revenue growth and operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
The sharp revenue increase indicates stronger commercial traction and product adoption. Sustained growth would improve operating leverage, expand the company’s presence in China’s ophthalmology market, and support future progress toward profitability.
Read all positive factors
Ocumension Therapeutics (1477) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.35B
Dividend YieldN/A
Average Volume (3M)351.11K
Price to Earnings (P/E)―
Beta (1Y)1.26
Revenue Growth77.55%
EPS Growth51.77%
CountryHK
Employees608
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.20
Shares Outstanding836,331,900
10 Day Avg. Volume265,430
30 Day Avg. Volume351,111
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)1.43
Price to Sales (P/S)6.54
P/FCF Ratio-14.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$7.92Price Target Upside4.90% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$1.07B
Ocumension Therapeutics Business Overview & Revenue Model
Company Description
Based in the People's Republic of China, Ocumension Therapeutics functions as a dedicated ophthalmic pharmaceutical platform. This company, along with its subsidiaries, is committed to the research, progression, and market introduction of therapeu...
How the Company Makes Money
null...
Ocumension Therapeutics Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
78
Positive
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 804.35M | 417.31M | 246.37M | 158.96M | 56.15M |
| Gross Profit | 360.92M | 225.06M | 144.37M | 102.92M | 36.94M |
| EBITDA | -29.95M | -188.03M | -320.62M | -359.98M | -249.81M |
| Net Income | -158.82M | -268.27M | -379.79M | -402.64M | -259.99M |
Balance Sheet | |||||
| Total Assets | 4.09B | 3.97B | 3.27B | 3.04B | 3.33B |
| Cash, Cash Equivalents and Short-Term Investments | 402.63M | 769.21M | 1.05B | 1.29B | 1.77B |
| Total Debt | 187.62M | 25.78M | 137.98M | 29.58M | 11.21M |
| Total Liabilities | 410.38M | 200.19M | 351.03M | 295.04M | 222.88M |
| Stockholders Equity | 3.68B | 3.77B | 2.92B | 2.75B | 3.11B |
Cash Flow | |||||
| Free Cash Flow | -358.65M | -408.97M | -539.79M | -510.66M | -861.66M |
| Operating Cash Flow | -105.29M | -178.83M | -177.93M | -200.66M | -196.85M |
| Investing Cash Flow | -361.46M | 275.91M | -259.78M | 229.15M | -1.35B |
| Financing Cash Flow | 118.04M | -213.79M | 108.66M | -9.22M | 668.85M |
Ocumension Therapeutics Technical Analysis
Neutral
7.55
Price Trends
5.35
Positive
5.68
Negative
6.61
Negative
Market Momentum
0.01
Negative
51.85
Neutral
50.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1477, the sentiment is Neutral. The current price of 7.55 is above the 20-day moving average (MA) of 5.30, above the 50-day MA of 5.35, and above the 200-day MA of 6.61, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 51.85 is Neutral, neither overbought nor oversold. The STOCH value of 50.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1477.
Ocumension Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$4.35B | -29.67 | -3.40% | ― | 77.55% | 51.77% | |
50 Neutral | HK$1.79B | 18.12 | 48.25% | ― | 88.38% | ― | |
47 Neutral | HK$3.05B | -5.54 | -79.24% | ― | -82.46% | 41.19% | |
46 Neutral | HK$1.36B | -5.58 | -14.41% | ― | 2.56% | 20.20% | |
43 Neutral | HK$405.28M | -1.62 | -27.54% | ― | 215.14% | 40.49% |
* Healthcare Sector Average
HK:1477
Ocumension Therapeutics
5.33
-4.17
-43.89%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.90
-2.88
-37.02%
HK:2181
Mabpharm Limited
0.44
-0.37
-45.63%
HK:6622
Zhaoke Ophthalmology Ltd.
2.49
-1.53
-38.18%
HK:6628
Transcenta Holding Limited
0.91
-3.64
-80.00%
HK:6955
Shandong Boan Biotechnology Company., Limited. Class H
2.85
-10.15
-78.08%
Ocumension Therapeutics Corporate Events
Ocumension Sets August Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
Ocumension Therapeutics has scheduled a board meeting for August 28, 2026 to review and approve the interim financial results for the six months ended June 30, 2026. The board will also consider whether to recommend an interim dividend, a decision...
Ocumension Wins China NMPA Nod for OT-502 Post-Surgery Eye Drug
Jul 2, 2026
Ocumension Therapeutics has secured approval from China’s National Medical Products Administration for the new drug application of OT-502, a single-dose, sustained-release dexamethasone intraocular suspension for treating postoperative ocula...
Ocumension CFO Resigns as Company Secretary Role Consolidated Under Chen
Jun 30, 2026
Ocumension Therapeutics announced the resignation of chief financial officer, joint company secretary and authorized representative Tim Ruan, effective June 30, 2026, citing personal reasons and confirming there is no disagreement with the board o...
Ocumension Secures Shareholder Backing at AGM and Refreshes Board Leadership
Jun 30, 2026
Ocumension Therapeutics reported that all resolutions proposed at its 2026 annual general meeting in Shanghai were approved by shareholders, including adoption of the 2025 financial statements, reappointment of Deloitte Touche Tohmatsu as auditor,...
Ocumension Details Board and Committee Structure to Highlight Governance
Jun 30, 2026
Ocumension Therapeutics has announced the current composition of its board of directors, detailing the roles of executive, non-executive, and independent non-executive members and confirming that the board is led by chairperson and non-executive d...
Ocumension Sets 2026 AGM to Approve Results, Board Changes and New Share Mandate
Jun 8, 2026
Ocumension Therapeutics has called its annual general meeting for June 30, 2026, in Shanghai, where shareholders will review and adopt the audited consolidated financial statements for the year ended December 31, 2025, and receive reports from the...
Ocumension Starts Phase III Trial Enrollment for Presbyopia Drug OT-802 in China
May 28, 2026
Ocumension Therapeutics has enrolled the first patient in a phase III clinical trial in China for OT-802, an innovative pilocarpine hydrochloride therapy designed to treat presbyopia, marking a key milestone in its late-stage development. Built on...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.